Growing optimism and a £2bn investor payout is a shot in the arm for this British giant
Last week’s full-year results from GlaxoSmithKline (GSK) do not answer every concern the sceptics may have regarding current ...
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.
ADVFN8d
GSK gets EU nod for expanded use of Jemperli in endometrial cancer
GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...
GSK outlines 2025 growth driven by specialty medicines and new product launches
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
pharmaphorum5d
GSK rides out vaccine sales weakness with cancer, HIV gains
GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...
Nasdaq5d
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
Jemperli added £149 million to GSK’s top line compared with £130 million in third-quarter 2024, driven by new patient starts across all regions. New blood cancer drug Ojjaara/Omjjara generated ...
Seeking Alpha5d
GSK outlines 2025 growth driven by specialty medicines and new product launches
Specialty medicines accounted for more than 80% of GSK's growth in 2024, led by oncology and respiratory immunology. Benlysta grew 14%, while Jemperli sales tripled, benefiting from expanded FDA ...
Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To Adult Patients With Advanced Endometrial Cancer
Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates ...